Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma

Melanoma Research

Volumn 25, Issue 4, 2015, Pages 302-305

  Sakji Dupré, Lilia ^a   Le Rhun, Emilie ^a,b   Templier, Carole ^a   Desmedt, Eve ^a   Blanchet, Benoit ^c   Mortier, Laurent ^a  

^a Lille Regional Teaching Hospital   (France)

^b Oscar Lambret Cancer Center   (France)

^c Cochin Hospital ^*  (France)

Author keywords

anti BRAF agents; blood brain barrier; brain metastases; cerebrospinal fluid concentration; leptomeningeal metastases; melanoma; vemurafenib

Indexed keywords

B RAF KINASE; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; BLOOD SAMPLING; BRAIN METASTASIS; BRAIN VENTRICLE PERITONEUM SHUNT; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUMBAR PUNCTURE; MALE; MELANOMA; MENINGEAL METASTASIS; METASTATIC B RAF KINASE V600 MUTATED MELANOMA; PRIORITY JOURNAL; STEREOTACTIC BODY RADIATION THERAPY; ANTAGONISTS AND INHIBITORS; BLOOD; BRAIN TUMOR; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; PATHOLOGY; PUNCTURE; SECONDARY; SKIN NEOPLASMS; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SPINAL PUNCTURE; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84936936447     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000162     Document Type: Article

References (23)

1. Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am 1996; 7:337-344.
2. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004; 22:1293-1300.
3. Kefford R, Maio M, Arance A, Nathan P, Blank C, Avril MF, et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm phase 2, multicenter study [abstract]. Pigment Cell Melanoma Res 2013; 26:965.
4. Peuvrel L, Saint-Jean M, Quéreux G, Brocard A, Khammari A, Knol AC, et al. Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib. J Neurooncol 2014; 120:147-154.
5. Pitz MW, Desai A, Grossman SA, Blakeley JO. Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neurooncol 2011; 104:629-638.
6. Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y, et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 2012; 70:399-405.
7. Zhao J, Chen M, Zhong W, Zhang L, Li L, Xiao Y, et al. Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin Lung Cancer 2013; 14:188-193.
8. Togashi Y, Masago K, Fukudo M, Terada T, Fujita S, Irisa K, et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol 2010; 5:950-955.
9. Togashi Y, Masago K, Fukudo M, Tsuchido Y, Okuda C, Kim YH, et al. Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother Pharmacol 2011; 68:1089-1092.
10. Fukudo M, Ikemi Y, Togashi Y, Masago K, Kim YH, Mio T, et al. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clin Pharmacokinet 2013; 52:593-609.
11. Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther 2012; 342:33-40.
12. Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Mol Pharm 2012; 9:3236-3245.
13. Zhen Y, Thomas-Schoemann A, Sakji L, Boudou-Rouquette P, Dupin N, Mortier L, et al. An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients. J Chromatogr B Analyt Technol Biomed Life Sci 2013; 928:93-97.
14. Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N Engl J Med 2011; 365:2439-2441.
15. Kolar GR, Miller-Thomas MM, Schmidt RE, Simpson JR, Rich KM, Linette GP. Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib. J Clin Oncol 2013; 31:e40-e43.
16. Melnik I, Lotem M, Yoffe B. A new role of vemurafenib as a neoadjuvant treatment of axillary and brain melanoma metastases. Case Rep Oncol Med 2013; 2013:794239.
17. Deeken JF, Löscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 2007; 13:1663-1674.
18. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 2010; 16:5664-5678.
19. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-819.
20. Westerhout J, Smeets J, Danhof M, de Lange ECM. The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid. J Pharmacokinet Pharmacodyn 2013; 40:327-342.
21. De Lange ECM, Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 2002; 41:691-703.
22. Shen DD, Artru AA, Adkison KK. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 2004; 56:1825-1857.
23. Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int 2013; 4 (Suppl 4): S265-S288.